PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 6 Issue 4

Tradition of “Traditional Medicine” - Bangladesh Perspective

Sheikh Mohammad Fazle Akbar, Chowdhury Faiz Hossain, Gazi Nurun Nahar Sultana, Sitesh Chandra Bachar, Shahabuddin K Choudhuri, Rezaul Karim, Sakirul Khan, Md. Zakir Sultan, Md. Enayet Ali Pramanik, Rakibul Hasan, Debabrata Karmakar, Rejina Afrin, Md. Abdur Rahim, Sheikh Mohammad Noor E Alam, Rokshana Begum, Ahmed Lutful Moben, Manas Saha, Md. Rezwanur Rahman, Musarrat Mahtab and Mamun Al Mahtab*

October 02, 2025

DOI : 10.56831/PSSRP-06-214

View PDF

Abstract

History of medicine has it’s roots in ancient times dating before the birth of Christ. Medicine has since then undergone massive evolution, more so in the 20th and 21st centuries. Traditional medicine has now mostly been replaced by evidence-based Allopathic medicine. However, the need to align traditional medicine with modern day medicine is being recognized. Countries like Bangladesh, with rich history of traditional systems of medicine, can be in the forefront. For this further work including research, appropriate policy for pharmaceutical industries etc. is now time demanding.

Keywords: Traditional medicine; history; Bangladesh; policy for pharmaceutical industry

References

  1. Cook HJ. “The history of medicine and scientific revolution”. The University of Chicago Press Journal 102.1 (2011).
  2. Saha D. “Potentials and Practice of Traditional Medicine in Bangladesh”. Al-Kufa University Journal for Biology 15.1 (2023).
  3. Qureshi Mahmud Shah. “Tribal Culture in Bangladesh”. Institute of Bangladesh Studies, Rajshahi University, Bangladesh (1984).
  4. Ghani Abdul. “Traditional Medicine”. Jahangirnagar University, Savar, Dhaka, Bangladesh (1990).
  5. Rashid KM, Khabiruddin and Md. And Hyder S. “Textbook of Community Medicine and Public Health”. 1st edn., RKH Publishers, Dhaka, Bangladesh (1992).
  6. Hatip Al Khatib I., et al. “Determination of the effectiveness of components of the herbal medicine Toki Shakuyaku San and fractions of Angelica acutiloba in improving the scopolamine induced impairment of rat’s spatial cognition in eight armed radial maze test”. JPharmacol Sci 96 (2004): 33-41.
  7. Ghani Abdul. “Medicinal Plants of Bangladesh: Chemical Constituents and Uses”. Asiatic Society of Bangladesh, Dhaka (1998).
  8. Paterson GR, Neilson JB and Roland CG. “History of medicine”. Canadian Medical Association Journal 127.10 (1982): 948.
  9. Alshammari TM. “Drug safety: The concept, inception and its importance in patients' health”. Saudi Pharm J 24.4 (2016): 405-12.
  10. Hanif M., et al. “Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic”. BMJ 311.6997 (1995): 88-91.
  11. Baranwal M, Kaur A and Kumar R. “Challenges in utilizing diethylene glycol and ethylene glycol as excipient: A thorough overview”. Pharmaspire 15.1 (2023): 8-15.
  12. Niazi SK. “Bridging the Regulatory Divide: A Dual-Pathway Framework Using SRA Approvals and AI Evaluation to Ensure Drug Quality in Developing Countries”. Pharmaceuticals (Basel) 18.7 (2025): 1024.
  13. Cavaleri M., et al. “A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems”. Lancet Glob Health 13.4 (2025): e769-e777.
  14. Lai Y., et al. “Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development”. Acta Pharm Sin B 12.6 (2022): 2751-2777.
  15. Hutt JA., et al. “Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus Vectors”. Toxicol Pathol 50.1 (2022): 118-146.
  16. Kang HN., et al. “Regulatory challenges with biosimilars: an update from 20 countries”. Ann N Y Acad Sci 1491.1 (2021): 42-59.
  17. Lexchin J. “Cost recovery by Health Canada and drug safety: a time-series analysis”. CMAJ Open 6.4 (2018): E471-E477.
  18. Hjorth R, van Hove L and Wickson F. What can nanosafety learn from drug development? The feasibility of "safety by design". Nanotoxicology 11.3 (2017): 305-312.
  19. Tyner K and Sadrieh N. “Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review”. Methods Mol Biol 697 (2011): 17-31.
  20. Alban S. “The 'precautionary principle' as a guide for future drug development”. Eur J Clin Invest 35 Suppl 1.Suppl 1 (2005): 33-44.
  21. Borgert CJ, Fuentes C and Burgoon LD. “Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety”. Arch Toxicol 95.12 (2021): 3651-3664.